Page 75 - Read Online

Quartuccio. Vessel Plus 2022;6:23 https://dx.doi.org/10.20517/2574-1209.2021.127 Page 3 of 3

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides.
Arthritis Rheum 2013;65:1-11. DOI PubMed
2. Hilhorst M, van Paassen P, Tervaert JW; Limburg Renal Registry. Proteinase 3-ANCA vasculitis versus myeloperoxidase-anca
vasculitis. J Am Soc Nephrol 2015;26:2314-27. DOI PubMed PMC
3. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-
23. DOI PubMed PMC
4. Quartuccio L, Treppo E, Valent F, De Vita S. Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated
analysis from clinical and administrative databases. Intern Emerg Med 2021;16:581-9. DOI PubMed PMC
5. Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis 2020;75:124-37. DOI PubMed
6. Geetha D, Jin Q, Scott J, et al. Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-
associated vasculitis. Kidney Int Rep 2018;3:1039-49. DOI PubMed PMC
7. Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens
2011;20:263-70. DOI PubMed PMC
8. Treppo E, Binutti M, Agarinis R, De Vita S, Quartuccio L. Rituximab induction and maintenance in ANCA-associated vasculitis: state
of the art and future perspectives. J Clin Med 2021;10:3773. DOI PubMed PMC
9. Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis.
N Engl J Med 2021;384:599-609. DOI PubMed
10. Osman MS, Tervaert JWC. Anti-neutrophil cytoplasmic antibodies (ANCA) as disease activity biomarkers in a "personalized medicine
approach" in ANCA-associated vasculitis. Curr Rheumatol Rep 2019;21:76. DOI PubMed